The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

Description

Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection. This clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain following intravitreal injections for patients with age-related macular degeneration. As of now, there is no definitive pain management technique following intravitreal injections. Loteprednol is a corticosteroid widely used in ophthalmology to treat pain and inflammation, however, it has not been studied as a treatment for pain following intravitreal injections. Our overall goal is to manage pain to improve quality of care after intravitreal injections. Participants will be given either loteprednol, or artificial tears following one visit for an intravitreal injection to test how effective loteprednol is in pain reduction. Pain levels will be assessed by asking participants over the phone about their pain from a scale of 0 to 10 at three different times over a 1-week period. Artificial tear and medication usage will also be tracked over a 1-week period.

Conditions

Age-Related Macular Degeneration

Study Overview

Study Details

Study overview

Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection. This clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain following intravitreal injections for patients with age-related macular degeneration. As of now, there is no definitive pain management technique following intravitreal injections. Loteprednol is a corticosteroid widely used in ophthalmology to treat pain and inflammation, however, it has not been studied as a treatment for pain following intravitreal injections. Our overall goal is to manage pain to improve quality of care after intravitreal injections. Participants will be given either loteprednol, or artificial tears following one visit for an intravitreal injection to test how effective loteprednol is in pain reduction. Pain levels will be assessed by asking participants over the phone about their pain from a scale of 0 to 10 at three different times over a 1-week period. Artificial tear and medication usage will also be tracked over a 1-week period.

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

Condition
Age-Related Macular Degeneration
Intervention / Treatment

-

Contacts and Locations

Roanoke

Vistar Eye Center, Roanoke, Virginia, United States, 24019

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All patients must have age-related macular degeneration and be undergoing intravitreal injections for treatment as defined by a retina specialist.
  • * Dementia
  • * Report baseline eye pain
  • * Use topical NSAIDs or steroids
  • * Patient under 18 years old
  • * History of corticosteroid responsive elevation in intraocular pressure
  • * Allergy to Loteprednol or Nepafenac
  • * Pre-existing chronic pain disorders
  • * Advanced Glaucoma
  • * Herpes zoster
  • * Allergy to local anesthetic or penicillin
  • * Patients unable to consent on own behalf
  • * Patients unable to communicate pain
  • * Pregnancy
  • * Incarceration

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Virginia Polytechnic Institute and State University,

Vishak John, MD, PRINCIPAL_INVESTIGATOR, Vistar Eye Center

Romulo Albuquerque, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Vistar Eye Center

Study Record Dates

2024-12-01